Salute e Benessere

The Secret to Turning Back Time: DermRays Skincare Device Makes Women Look 10…

According to the DermRays R&D team, an exciting 1450nm laser skincare device is currently in development and is expected to launch later this year. "We are committed to continuously innovating to meet women's skincare needs," says Dr. Yang Lin, dermatology consultant for DermRays. "Our upcoming laser technology will further enhance skin rejuvenation, offering even more transformative results. According to the DermRays R&D team, an exciting 1450nm laser skincare device is…
PR Newswire
10/05/2025

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), May 9, 2025 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.FMR LLCOn May 2, 2025, Nyxoah received a transparency notification from FMR LLC. Based on the...
Nasdaq GlobeNewswire
09/05/2025

Oculis Publishes Invitation to the Annual General Meeting

/ ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the followinglink. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis websitehere. Oculis will...
Nasdaq GlobeNewswire
09/05/2025

FEELM Launches New Pod Solution Product Series, Empowering the Industry to Enter…

"By closely observing global market trends and policy shifts, we have continuously enhanced the competitiveness of our product solutions in recent years. We are committed to driving market success with a dual approach of 'technology+product', helping more clients seize market opportunities, control future industry trends, and gain a competitive edge," said REX Zhang, Head of Product Marketing at FEELM. "By closely observing global market trends and policy shifts, we have…
PR Newswire
09/05/2025

Report of transactions of shares and related securities of Bavarian Nordic by…

COPENHAGEN, Denmark, May 9, 2025– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.The transactions concern the vesting of restricted stock units (RSUs) by members...
Nasdaq GlobeNewswire
09/05/2025

Injectable Drug Delivery Market worth US$1,034.78 billion by 2030 with 8.4% CAGR…

Recent developments in this market include the introduction of smart injectors that feature connectivity capabilities, the expansion of large-volume subcutaneous delivery systems, and partnerships between pharmaceutical companies and device developers aimed at creating biologics-compatible delivery platforms. Many companies also invest in sustainable and reusable injection systems, especially in Europe, to comply with environmental regulations. Recent developments in this market include the...
PR Newswire
09/05/2025

Artificial Intelligence (AI) in Healthcare Market worth US$110.61 billion by…

Browse in-depth TOC on "Artificial Intelligence (AI) in Healthcare Market" Browse in-depth TOC on "Artificial Intelligence (AI) in Healthcare Market" 882 - Tables 61 - Figures 738 - Pages By tools,the Artificial Intelligence (AI) in healthcare market for machine learning has been bifurcated into deep learning, supervised learning, reinforcement learning, unsupervised learning, and other machine learning technologies. The deep learning segment accounted for the largest…
PR Newswire
09/05/2025

In Vitro Diagnostics Market worth US$157,632.5 million by 2030 with 7.6% CAGR |…

Browse in-depth TOC on "In Vitro Diagnostics Market" Browse in-depth TOC on "In Vitro Diagnostics Market" 882 - Tables 67 - Figures 739 - Pages By product,the in vitro diagnostics market is segmented into reagents & kits, instruments, and data management software and services. In 2024, the reagents & kits segment accounted for the highest growth rate in the in vitro diagnostics market. This is due to an increasing need for quick and accurate diagnostic tests...
PR Newswire
09/05/2025

Alvotech Meets Investors and Participates in Fireside Chat At the BofA…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2025, at 11:40 am -12:10 pm EDT (15:40-16:10 GMT /...
Nasdaq GlobeNewswire
09/05/2025

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical…

SOUTH SAN FRANCISCO, Calif., May09, 2025(GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral...
Nasdaq GlobeNewswire
09/05/2025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 9 May 2025— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by...
Nasdaq GlobeNewswire
09/05/2025

Transactions of Managers and Closely Associated Persons

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition at the market opening of 320,000 shares in Alvotech at ISK 1,255 per share, by Robert Wessman, Chairman and CEO.
Nasdaq GlobeNewswire
09/05/2025

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New…

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May09, 2025(GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced publication...
Nasdaq GlobeNewswire
09/05/2025

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent…

~ AMT-130 granted Breakthrough Therapy designation by FDA ~~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies &...
Nasdaq GlobeNewswire
09/05/2025

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for three months with intranasal foralumab under an expanded access program...
Nasdaq GlobeNewswire
09/05/2025

Osteotec Signs Exclusive Distribution Agreement with icotec ag to advance Spine…

Headquartered in Altstätten, Switzerland, icotec develops and manufactures innovative, radiolucent implants derived from BlackArmor® Carbon/PEEK material for the operative treatment of tumour diseases of the spine and other indications. Headquartered in Altstätten,Switzerland, icotec develops and manufactures innovative, radiolucent implants derived from BlackArmor® Carbon/PEEK material for the operative treatment of tumour diseases of the spine and other indications. icotec's BlackArmor®...
PR Newswire
09/05/2025

Implantica publishes Interim Report January - March 2025 (Q1)

Significant events in the first quarter of 2025 Significant events in the first quarter of 2025 Significant events after the end of the period Financial summary first quarter 2025 Telephone conference Implantica will hold a teleconference on9 May 2025at 15:00 (CEST) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to...
PR Newswire
09/05/2025

Ulrika Kolsrud new President and CEO of Essity

"I am honored that the Board of Directors has entrusted me with leading Essity in the next development phase. I see great potential in the company, and it is with great enthusiasm that I take on this assignment. I look forward to working with Essity's fantastic employees to make a real difference for our customers, deliver profitable growth, and take Essity to the next level," says Ulrika Kolsrud. "I am honored that the Board of Directors has entrusted me with leading Essity in…
PR Newswire
09/05/2025

Bavarian Nordic Announces Interim Results for the First Three Months of 2025

COPENHAGEN, Denmark , May 9, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million, reflecting a strong performance in both Travel Health and Public Preparedness.Travel Health revenue increased by 52% to DKK 680 million compared to the first quarter of 2024, primarily driven by increased demand for rabies and tick-borne...
Nasdaq GlobeNewswire
09/05/2025

Invitation to attend the annual and the extraordinary shareholders' meetings of…

REGULATED INFORMATIONMay 9, 2025, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH)Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the annual and the extraordinary shareholders' meetings of the Companyto be held on June 11, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders' meeting of the Company, to be held onWednesday, June 11, 2025 at 2:00 p...
Nasdaq GlobeNewswire
09/05/2025

Zealand Pharma announces closing of collaboration and license agreement with…

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with RocheCopenhagen, Denmark, May 9, 2025– Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Rocheannounced on March 12, 2025have been...
Nasdaq GlobeNewswire
09/05/2025

LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across…

Novartis/Alnylam Pharmaceuticals' LEQVIO (inclisiran) Overview Novartis/Alnylam Pharmaceuticals' LEQVIO (inclisiran) Overview LEQVIO (inclisiran) is a first-of-its-kind therapy developed by Novartis based on small interfering RNA (siRNA) technology. It targets the mRNA of PCSK9 (proprotein convertase subtilisin/kexin type 9), reducing the production of this protein in the liver. Unlike traditional treatments, LEQVIO lowers LDL-C levels by enhancing the liver's ability to absorb and...
PR Newswire
08/05/2025

LUPKYNIS Strengthens Market Position as Demand for Lupus Nephritis Treatment…

Aurinia Pharmaceuticals/Otsuka Pharmaceutical's LUPKYNIS (voclosporin) Overview Aurinia Pharmaceuticals/Otsuka Pharmaceutical's LUPKYNIS (voclosporin) Overview LUPKYNIS (voclosporin) is an oral immunosuppressant classified as a calcineurin inhibitor (CNI), shown to improve both short- and long-term outcomes in adult patients with active lupus nephritis when used alongside standard immunosuppressive therapies. By targeting calcineurin, LUPKYNIS helps suppress cytokine activity, inhibits...
PR Newswire
08/05/2025

Theriva Biologics Announces Closing of $7.5 Million Public Offering

The Company intends to use the net proceeds from this Offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up. The Company may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although it currently has no commitments or agreements with respect to any such investments or acquisitions.A.G.P./Alliance Global Partners acted as the sole placement agent for...
Nasdaq GlobeNewswire
08/05/2025
Altri  Comunicati